Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial
Summary Background The efficacy of ASA for prevention of graft failure following CABG surgery may be limited by incomplete platelet inhibition due to increased post‐operative platelet turnover. Objectives To determine whether acetyl‐salicylic acid (ASA) 325 mg once‐daily or 81 mg four‐times daily ov...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and haemostasis 2015-03, Vol.13 (3), p.448-456 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 456 |
|---|---|
| container_issue | 3 |
| container_start_page | 448 |
| container_title | Journal of thrombosis and haemostasis |
| container_volume | 13 |
| creator | Paikin, J. S. Hirsh, J. Ginsberg, J. S. Weitz, J. I. Chan, N. C. Whitlock, R. P. Pare, G. Johnston, M. Eikelboom, J. W. |
| description | Summary
Background
The efficacy of ASA for prevention of graft failure following CABG surgery may be limited by incomplete platelet inhibition due to increased post‐operative platelet turnover.
Objectives
To determine whether acetyl‐salicylic acid (ASA) 325 mg once‐daily or 81 mg four‐times daily overcomes the impaired response to ASA 81 mg once‐daily in post‐operative coronary artery bypass graft (CABG) patients.
Methods
We randomized 110 patients undergoing CABG surgery to either ASA 81 mg once‐daily, 81 mg four times daily or 325 mg once‐daily and compared their effects on serum thromboxane B2 (TXB2) suppression and arachidonate‐induced platelet aggregation.
Results
One hundred patients were included in the final analysis. Platelet counts fell after surgery, reached a nadir on day 2, and then gradually increased. Although there was near complete suppression of TXB2 on the second or third post‐operative day, TXB2 levels increased in parallel with the rise in platelet count on subsequent days. This increase was most marked in patients receiving ASA 81 mg once‐daily and less evident in those receiving ASA four times daily. On post‐operative day 4, (i) median TXB2 levels were lower with four times daily ASA than with either ASA 81 mg once‐daily (1.1 ng/mL; Quartile(Q) Q1,Q3: 0.5, 2.4 and 13.3 ng/mL; Q1,Q3: 7.8, 30.8 ng/mL, respectively; P |
| doi_str_mv | 10.1111/jth.12832 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1659778975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3610610841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-e542de971d621552501072acb6e858a8eeb9b6b36f92c7053528bebfd917eecb3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhS1ERUthwQsgS2zo4raxfZ047K4q6I-KWFDWkX8mxVe-cbCdorDiEXigPg1PwtC07LBkeXx85htZh5BXrDpmuE625esx40rwJ-SASaFWjRL108e6FWKfPM95W1Wslbx6Rva5lOt6XcsDcvdxCsWPAajTPszUxQyZxp5qC2UOv3_-yjp4O-NGyTv6dvN5c0TjLSQbd0ATuMmCo2PQBQIUFPIYhwy0RBoHC0hYyNhHdV8gURtTHHSaqU54namZR50zvUn4TPOUblB8RzUdfYgI1IOLO_8Dh9g4lBRDwLIkr8MLstfrkOHlw3lIvnx4f316vrr6dHZxurlaWaEUX4Fccwdtw1zNmZRcVqxquLamBiWVVgCmNbURdd9y21RSSK4MmN61rAGwRhySNwt3TPHbBLl02zilAUd2rJZt06i2keg6Wlw2xZwT9N2Y_A7_2bGq-5tThzl19zmh9_UDcTI7cP-cj8Gg4WQxfPcB5v-Tusvr8wX5B5jXom8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1659778975</pqid></control><display><type>article</type><title>Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Paikin, J. S. ; Hirsh, J. ; Ginsberg, J. S. ; Weitz, J. I. ; Chan, N. C. ; Whitlock, R. P. ; Pare, G. ; Johnston, M. ; Eikelboom, J. W.</creator><creatorcontrib>Paikin, J. S. ; Hirsh, J. ; Ginsberg, J. S. ; Weitz, J. I. ; Chan, N. C. ; Whitlock, R. P. ; Pare, G. ; Johnston, M. ; Eikelboom, J. W.</creatorcontrib><description>Summary
Background
The efficacy of ASA for prevention of graft failure following CABG surgery may be limited by incomplete platelet inhibition due to increased post‐operative platelet turnover.
Objectives
To determine whether acetyl‐salicylic acid (ASA) 325 mg once‐daily or 81 mg four‐times daily overcomes the impaired response to ASA 81 mg once‐daily in post‐operative coronary artery bypass graft (CABG) patients.
Methods
We randomized 110 patients undergoing CABG surgery to either ASA 81 mg once‐daily, 81 mg four times daily or 325 mg once‐daily and compared their effects on serum thromboxane B2 (TXB2) suppression and arachidonate‐induced platelet aggregation.
Results
One hundred patients were included in the final analysis. Platelet counts fell after surgery, reached a nadir on day 2, and then gradually increased. Although there was near complete suppression of TXB2 on the second or third post‐operative day, TXB2 levels increased in parallel with the rise in platelet count on subsequent days. This increase was most marked in patients receiving ASA 81 mg once‐daily and less evident in those receiving ASA four times daily. On post‐operative day 4, (i) median TXB2 levels were lower with four times daily ASA than with either ASA 81 mg once‐daily (1.1 ng/mL; Quartile(Q) Q1,Q3: 0.5, 2.4 and 13.3 ng/mL; Q1,Q3: 7.8, 30.8 ng/mL, respectively; P < 0.0001) or ASA 325 mg once‐daily (3.4 ng/mL; Q1,Q3: 2.0, 8.2 ng/mL; P = 0.002), and (ii) ASA given four times daily was more effective than ASA 81 mg once‐daily and 325 mg once‐daily at suppressing platelet aggregation.
Conclusions
Four times daily ASA is more effective than ASA 81 and 325 mg once‐daily at suppressing serum TXB2 formation and platelet aggregation immediately following CABG surgery.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/jth.12832</identifier><identifier>PMID: 25546465</identifier><language>eng</language><publisher>England: Elsevier Limited</publisher><subject>Aged ; aspirin ; Aspirin - administration & dosage ; Aspirin - adverse effects ; Biomarkers - blood ; Blood Platelets - drug effects ; Blood Platelets - metabolism ; coronary artery bypass ; Coronary Artery Bypass - adverse effects ; Drug Administration Schedule ; Drug Resistance ; Female ; Humans ; Male ; Middle Aged ; Ontario ; perioperative period ; Pilot Projects ; Platelet Aggregation - drug effects ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Count ; Platelet Function Tests ; Thromboxane B2 - blood ; Time Factors ; Treatment Outcome</subject><ispartof>Journal of thrombosis and haemostasis, 2015-03, Vol.13 (3), p.448-456</ispartof><rights>2014 International Society on Thrombosis and Haemostasis</rights><rights>2014 International Society on Thrombosis and Haemostasis.</rights><rights>Copyright © 2015 International Society on Thrombosis and Haemostasis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-e542de971d621552501072acb6e858a8eeb9b6b36f92c7053528bebfd917eecb3</citedby><cites>FETCH-LOGICAL-c3882-e542de971d621552501072acb6e858a8eeb9b6b36f92c7053528bebfd917eecb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25546465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paikin, J. S.</creatorcontrib><creatorcontrib>Hirsh, J.</creatorcontrib><creatorcontrib>Ginsberg, J. S.</creatorcontrib><creatorcontrib>Weitz, J. I.</creatorcontrib><creatorcontrib>Chan, N. C.</creatorcontrib><creatorcontrib>Whitlock, R. P.</creatorcontrib><creatorcontrib>Pare, G.</creatorcontrib><creatorcontrib>Johnston, M.</creatorcontrib><creatorcontrib>Eikelboom, J. W.</creatorcontrib><title>Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Summary
Background
The efficacy of ASA for prevention of graft failure following CABG surgery may be limited by incomplete platelet inhibition due to increased post‐operative platelet turnover.
Objectives
To determine whether acetyl‐salicylic acid (ASA) 325 mg once‐daily or 81 mg four‐times daily overcomes the impaired response to ASA 81 mg once‐daily in post‐operative coronary artery bypass graft (CABG) patients.
Methods
We randomized 110 patients undergoing CABG surgery to either ASA 81 mg once‐daily, 81 mg four times daily or 325 mg once‐daily and compared their effects on serum thromboxane B2 (TXB2) suppression and arachidonate‐induced platelet aggregation.
Results
One hundred patients were included in the final analysis. Platelet counts fell after surgery, reached a nadir on day 2, and then gradually increased. Although there was near complete suppression of TXB2 on the second or third post‐operative day, TXB2 levels increased in parallel with the rise in platelet count on subsequent days. This increase was most marked in patients receiving ASA 81 mg once‐daily and less evident in those receiving ASA four times daily. On post‐operative day 4, (i) median TXB2 levels were lower with four times daily ASA than with either ASA 81 mg once‐daily (1.1 ng/mL; Quartile(Q) Q1,Q3: 0.5, 2.4 and 13.3 ng/mL; Q1,Q3: 7.8, 30.8 ng/mL, respectively; P < 0.0001) or ASA 325 mg once‐daily (3.4 ng/mL; Q1,Q3: 2.0, 8.2 ng/mL; P = 0.002), and (ii) ASA given four times daily was more effective than ASA 81 mg once‐daily and 325 mg once‐daily at suppressing platelet aggregation.
Conclusions
Four times daily ASA is more effective than ASA 81 and 325 mg once‐daily at suppressing serum TXB2 formation and platelet aggregation immediately following CABG surgery.</description><subject>Aged</subject><subject>aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - adverse effects</subject><subject>Biomarkers - blood</subject><subject>Blood Platelets - drug effects</subject><subject>Blood Platelets - metabolism</subject><subject>coronary artery bypass</subject><subject>Coronary Artery Bypass - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ontario</subject><subject>perioperative period</subject><subject>Pilot Projects</subject><subject>Platelet Aggregation - drug effects</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Count</subject><subject>Platelet Function Tests</subject><subject>Thromboxane B2 - blood</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1TAQhS1ERUthwQsgS2zo4raxfZ047K4q6I-KWFDWkX8mxVe-cbCdorDiEXigPg1PwtC07LBkeXx85htZh5BXrDpmuE625esx40rwJ-SASaFWjRL108e6FWKfPM95W1Wslbx6Rva5lOt6XcsDcvdxCsWPAajTPszUxQyZxp5qC2UOv3_-yjp4O-NGyTv6dvN5c0TjLSQbd0ATuMmCo2PQBQIUFPIYhwy0RBoHC0hYyNhHdV8gURtTHHSaqU54namZR50zvUn4TPOUblB8RzUdfYgI1IOLO_8Dh9g4lBRDwLIkr8MLstfrkOHlw3lIvnx4f316vrr6dHZxurlaWaEUX4Fccwdtw1zNmZRcVqxquLamBiWVVgCmNbURdd9y21RSSK4MmN61rAGwRhySNwt3TPHbBLl02zilAUd2rJZt06i2keg6Wlw2xZwT9N2Y_A7_2bGq-5tThzl19zmh9_UDcTI7cP-cj8Gg4WQxfPcB5v-Tusvr8wX5B5jXom8</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Paikin, J. S.</creator><creator>Hirsh, J.</creator><creator>Ginsberg, J. S.</creator><creator>Weitz, J. I.</creator><creator>Chan, N. C.</creator><creator>Whitlock, R. P.</creator><creator>Pare, G.</creator><creator>Johnston, M.</creator><creator>Eikelboom, J. W.</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>201503</creationdate><title>Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial</title><author>Paikin, J. S. ; Hirsh, J. ; Ginsberg, J. S. ; Weitz, J. I. ; Chan, N. C. ; Whitlock, R. P. ; Pare, G. ; Johnston, M. ; Eikelboom, J. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-e542de971d621552501072acb6e858a8eeb9b6b36f92c7053528bebfd917eecb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - adverse effects</topic><topic>Biomarkers - blood</topic><topic>Blood Platelets - drug effects</topic><topic>Blood Platelets - metabolism</topic><topic>coronary artery bypass</topic><topic>Coronary Artery Bypass - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ontario</topic><topic>perioperative period</topic><topic>Pilot Projects</topic><topic>Platelet Aggregation - drug effects</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Count</topic><topic>Platelet Function Tests</topic><topic>Thromboxane B2 - blood</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paikin, J. S.</creatorcontrib><creatorcontrib>Hirsh, J.</creatorcontrib><creatorcontrib>Ginsberg, J. S.</creatorcontrib><creatorcontrib>Weitz, J. I.</creatorcontrib><creatorcontrib>Chan, N. C.</creatorcontrib><creatorcontrib>Whitlock, R. P.</creatorcontrib><creatorcontrib>Pare, G.</creatorcontrib><creatorcontrib>Johnston, M.</creatorcontrib><creatorcontrib>Eikelboom, J. W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paikin, J. S.</au><au>Hirsh, J.</au><au>Ginsberg, J. S.</au><au>Weitz, J. I.</au><au>Chan, N. C.</au><au>Whitlock, R. P.</au><au>Pare, G.</au><au>Johnston, M.</au><au>Eikelboom, J. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2015-03</date><risdate>2015</risdate><volume>13</volume><issue>3</issue><spage>448</spage><epage>456</epage><pages>448-456</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Summary
Background
The efficacy of ASA for prevention of graft failure following CABG surgery may be limited by incomplete platelet inhibition due to increased post‐operative platelet turnover.
Objectives
To determine whether acetyl‐salicylic acid (ASA) 325 mg once‐daily or 81 mg four‐times daily overcomes the impaired response to ASA 81 mg once‐daily in post‐operative coronary artery bypass graft (CABG) patients.
Methods
We randomized 110 patients undergoing CABG surgery to either ASA 81 mg once‐daily, 81 mg four times daily or 325 mg once‐daily and compared their effects on serum thromboxane B2 (TXB2) suppression and arachidonate‐induced platelet aggregation.
Results
One hundred patients were included in the final analysis. Platelet counts fell after surgery, reached a nadir on day 2, and then gradually increased. Although there was near complete suppression of TXB2 on the second or third post‐operative day, TXB2 levels increased in parallel with the rise in platelet count on subsequent days. This increase was most marked in patients receiving ASA 81 mg once‐daily and less evident in those receiving ASA four times daily. On post‐operative day 4, (i) median TXB2 levels were lower with four times daily ASA than with either ASA 81 mg once‐daily (1.1 ng/mL; Quartile(Q) Q1,Q3: 0.5, 2.4 and 13.3 ng/mL; Q1,Q3: 7.8, 30.8 ng/mL, respectively; P < 0.0001) or ASA 325 mg once‐daily (3.4 ng/mL; Q1,Q3: 2.0, 8.2 ng/mL; P = 0.002), and (ii) ASA given four times daily was more effective than ASA 81 mg once‐daily and 325 mg once‐daily at suppressing platelet aggregation.
Conclusions
Four times daily ASA is more effective than ASA 81 and 325 mg once‐daily at suppressing serum TXB2 formation and platelet aggregation immediately following CABG surgery.</abstract><cop>England</cop><pub>Elsevier Limited</pub><pmid>25546465</pmid><doi>10.1111/jth.12832</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-7933 |
| ispartof | Journal of thrombosis and haemostasis, 2015-03, Vol.13 (3), p.448-456 |
| issn | 1538-7933 1538-7836 1538-7836 |
| language | eng |
| recordid | cdi_proquest_journals_1659778975 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged aspirin Aspirin - administration & dosage Aspirin - adverse effects Biomarkers - blood Blood Platelets - drug effects Blood Platelets - metabolism coronary artery bypass Coronary Artery Bypass - adverse effects Drug Administration Schedule Drug Resistance Female Humans Male Middle Aged Ontario perioperative period Pilot Projects Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Count Platelet Function Tests Thromboxane B2 - blood Time Factors Treatment Outcome |
| title | Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T07%3A38%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multiple%20daily%20doses%20of%20acetyl%E2%80%90salicylic%20acid%20(ASA)%20overcome%20reduced%20platelet%20response%20to%20once%E2%80%90daily%20ASA%20after%20coronary%20artery%20bypass%20graft%20surgery:%20a%20pilot%20randomized%20controlled%20trial&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=Paikin,%20J.%20S.&rft.date=2015-03&rft.volume=13&rft.issue=3&rft.spage=448&rft.epage=456&rft.pages=448-456&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/jth.12832&rft_dat=%3Cproquest_cross%3E3610610841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1659778975&rft_id=info:pmid/25546465&rfr_iscdi=true |